Management of aggressive pituitary adenomas: Current treatment strategies

Pituitary

Volumn 12, Issue 3, 2009, Pages 256-260

  Buchfelder, Michael ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Chemotherapy; Pharmacotherapy; Pituitary adenoma; Radiotherapy; Surgery

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; SOMATOSTATIN DERIVATIVE; TEMOZOLOMIDE;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS FUNCTION; MULTIMODALITY CANCER THERAPY; NAUSEA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PROTEIN EXPRESSION; REOPERATION; SURGICAL APPROACH; SURGICAL TECHNIQUE; TRANSSPHENOIDAL SURGERY; TREATMENT RESPONSE; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

DACARBAZINE; DOPAMINE AGONISTS; ERGOLINES; FEMALE; HUMANS; MALE; PITUITARY NEOPLASMS; SOMATOSTATIN;

EID: 67849084599     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-008-0153-z     Document Type: Article

References (25)

1. Schloffer H (1907) Erfolgreiche Operation eines Hypophysentumors auf nasalem Wege. Wien Klin Wochenschr 20:621-624
2. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485-534. doi: 10.1210/ er.2005-9998
3. Biller BM, Molitch ME, Vance ML et al (1996) Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J Clin Endocrinol Metab 81(6):2338-2343. doi: 10.1210/ jc.81.6.2338
4. Colao A, Di Sarno A, Landi ML et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574-3579. doi: 10.1210/jc.82.11.3574
5. Colao A, Di Sarno A, Landi ML et al (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247-2252. doi: 10.1210/ jc.85.6.2247
6. Ferrari CI, Abs R, Bevan JS et al (1997) Treatment of macroprolactinoma with cabergoline: A study of 85 patients. Clin Endocrinol (Oxf) 46(4):409-413. doi: 10.1046/j.1365-2265.1997.1300952.x
7. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331(14):904-909. doi: 10.1056/NEJM199410063311403
8. Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 84(7):2518-2522. doi: 10.1210/jc.84.7.2518
9. Zatelli MC, Ambrosio MR, Bondanelli M, Uberti EC (2007) Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds. Eur J Endocrinol 156(suppl 1):S29-S35. doi: 10.1530/eje.1.02352
10. Vance ML, Laws ER Jr (2005) Role of medical therapy in the management of acromegaly. Neurosurgery 56(5):877-885. discussion-85
11. Caron P, Bex M, Cullen DR et al (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf) 60(6):734-740. doi: 10.1111/ j.1365-2265.2004.02045.x
12. Maiza JC, Vezzosi D, Matta M et al (2007) Long-term (upto 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67(2):282-289. doi: 10.1111/j.1365-2265.2007.02878.x
13. Mercado M, Borges F, Bouterfa H et al (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf) 66(6):859-868. doi: 10.1111/j.1365-2265.2007.02825.x
14. Karavitaki N, Turner HE, Adams CB et al (2008) Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 68(6):970-975. doi: 10.1111/ j.1365-2265.2007.03139.x
15. Bevan JS (2005) Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90(3):1856-1863. doi: 10.1210/jc.2004-1093
16. Colao A, Marzullo P, Ferone D et al (1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest 22(1):40-47
17. Cozzi R, Barausse M, Sberna M et al (2000) Lanreotide 60 mg, a longer-acting somatostatin analog: Tumor shrinkage and hormonal normalization in acromegaly. Pituitary 3(4):231-238. doi: 10.1023/ A:1012832230598
18. Colao A, Pivonello R, Auriemma RS et al (2006) Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 91(6):2112-2118. doi: 10.1210/jc.2005-2110
19. Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M (2007) Surgical treatment of giant pituitary adenomas: Strategies and results in a series of 95 consecutive patients. Neurosurgery 60(6):993-1002 discussion 3-4
20. Fadul CE, Kominsky AL, Meyer LP et al (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105(4):621-626. doi: 10.3171/jns.2006.105.4.621
21. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: A novel treatment for pituitary carcinoma. Lancet Oncol 7(6):518-520. doi: 10.1016/S1470-2045(06)70728-8
22. Syro LV, Uribe H, Penagos LC et al (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65(4):552-553. doi: 10.1111/ j.1365-2265.2006.02653.x
23. Kovacs K, Horvath E, Syro LV et al (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Hum Pathol 38(1):185-189. doi: 10.1016/j.humpath.2006.07.014
24. Neff LM, Weil M, Cole A et al (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81-86. doi: 10.1007/s11102-007-0014-1
25. Kovacs K, Scheithauer BW, Lombardero M et al (2008) MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy. Acta Neuropathol 115(2):261-262. doi: 10.1007/ s00401-007-0279-5